Cargando…
N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial
BACKGROUND: Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) constitute to be a high-risk population for the development of contrast-induced nephropathy (CIN), in which the incidence of CIN is estimated to be as high as 50%. We performed this trial to assess the efficacy of N-ac...
Autores principales: | Amini, Manouchehr, Salarifar, Mojtaba, Amirbaigloo, Alireza, Masoudkabir, Farzad, Esfahani, Fatemeh |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714294/ https://www.ncbi.nlm.nih.gov/pubmed/19563648 http://dx.doi.org/10.1186/1745-6215-10-45 |
Ejemplares similares
-
Comparison between theophylline, N-acetylcysteine, and theophylline plus
N-acetylcysteine for the prevention of contrast-induced nephropathy
por: Arabmomeni, Morteza, et al.
Publicado: (2015) -
Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy
por: Richter, Sara K., et al.
Publicado: (2015) -
Evaluation of the protective effect of N-acetylcysteine on contrast media nephropathy
por: Pezeshgi, Aiyoub, et al.
Publicado: (2015) -
N-acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Narrative Review
por: Jo, Sang-Ho
Publicado: (2011) -
Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Publicado: (2009)